Collectively, FKC inhibits glucose metabolism and tumor angiogenesis in NPC by targeting the HSP90B1/EGFR/PI3K/Akt/mTOR signaling axis. This evidence concerns the gene HSP90B1 and nasopharyngeal carcinoma.